Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-Congress-2022-1000x250

The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community. 

The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress. The industry has no influence on the content of the programme or speaker selection. 

View the complete ESMO Congress 2022 programme online

The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics

Multiplex-Biomarker-Profiling-in-Contemporary-Oncology-Thumb

Saturday, 10 September 2022
13:00-14:30 CEST (Central European Summer Time)
Congress Hall 7 – Auditorium 7.3.H-Honfleur
This educational activity is provided by ESMO and supported by Lilly and Thermo Fisher Scientific

View the ESMO colloquium details

Learning Objectives
  • To provide an update on the evidence for clinical benefit from tumour-agnostic precision therapeutics and propose a framework for evidence generation
  • To provide insights in the interactions between molecular target and tissue context in the era of molecular oncology and propose a taxonomy for targeted agents
  • To present current indications for multiplex NGS tumour testing for actionable biomarkers
  • To highlight NGS implementation challenges from preanalytics, analytics, reimbursement, reporting and interpretation

Optimising outcomes of patients with advanced renal cancer

Multiplex-Biomarker-Profiling-in-Contemporary-Oncology-Thumb

Sunday, 11 September 2022
13:00-14:30 CEST (Central European Summer Time)
Congress Hall 7 – Auditorium 7.3.O-Orléans
This educational activity is provided by ESMO and supported by Eisai Europe Ltd.

View the ESMO colloquium details

Learning Objectives
  • To provide updates on insights in the biology of advanced clear cell cancer 
  • To provide information on state of the art management of patients with clear cell renal cell carcinoma
  • To explore prognostication algorithms and clinical research developments in advanced renal cell cancer

Targeting HER2 in advanced breast cancer: Successes and perspectives

Multiplex-Biomarker-Profiling-in-Contemporary-Oncology-Thumb

Monday, 12 September 2022
13:00-14:30 CEST (Central European Summer Time)
Congress Hall 7 – Auditorium 7.3.O-Orléans
This educational activity is provided by ESMO and supported by Daiichi-Sankyo and AstraZeneca

View the ESMO colloquium details

Learning Objectives
  • To provide updates on the emerging treatment algorithms for the management of patients with HER2+ advanced breast cancer 
  • To provide insights on clinical research in HER2-low advanced breast cancer
  • To explore preclinical and early clinical developments of ADC-based combinations with targeted agents in HER2+ metastatic breast cancer

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.